Article Information
- Received March 5, 2009
- Revision received April 13, 2009
- Accepted April 23, 2009
- First published June 3, 2009.
- Version of record published June 3, 2009.
Author Information
- Atheir I. Abbas 1 ,*,
- Prem N. Yadav 2 ,*,
- Wei-Dong Yao 7 , 8 , 9 , 10 ,
- Margaret I. Arbuckle 11 ,
- Seth G. N. Grant 11 , 12 ,
- Marc G. Caron 7 , 8 , 9 , and
- Bryan L. Roth 1 , 2 , 3 , 4 , 5 , 6
- 1Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106,
- Departments of 2Pharmacology,
- 3Medicinal Chemistry, and
- 4Psychiatry,
- 5Lineberger Cancer Center, and
- 6National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill, North Carolina 27599,
- Departments of 7Cell Biology,
- 8Medicine, and
- 9Neurobiology, Duke University Medical Center, Durham, North Carolina 27710,
- 10Department of Psychiatry, Division of Neurosciences, New England Primate Research Center, Harvard Medical School, Boston, Massachusetts 02115,
- 11Division of Neuroscience, University of Edinburgh, Edinburgh EH8 9JZ, United Kingdom, and
- 12Genes to Cognition Programme, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, United Kingdom
- Correspondence should be addressed to Dr. Bryan L. Roth, Department of Pharmacology, University of North Carolina, 4009 Genetics Medicine Building, CB#7365, Chapel Hill, NC 27599-7365. bryan_roth{at}med.unc.edu
Author contributions
-
↵*A.I.A. and P.N.Y. contributed equally to this work.
Disclosures
- Received March 5, 2009.
- Revision received April 13, 2009.
- Accepted April 23, 2009.
-
A.I.A., P.N.Y., and B.L.R. were supported by Grants NIMH61887 and U19MH82441 from the National Institute of Mental Health–National Institutes of Health (NIH), and the National Institute of Mental Health Psychoactive Drug Screening Program; B.L.R. received additional support as a National Alliance for Research on Schizophrenia and Depression (NARSAD) Distinguished Investigator. A.I.A. was also supported by the Case Western Reserve University (CWRU) Medical Scientist Training Program and NIH Grant T32 GM007250. W.-D.Y. received funding support from the following: DA021420 (National Institute on Drug Abuse), NS057311 (National Institute of Neurological Disorders and Stroke), RR00168 (New England Primate Research Center). M.G.C. was funded by NIH Grants NS-19576 and MH-73853. M.G.C. is the NARSAD Lattner Foundation Distinguished Investigator. S.G.N.G. is funded by the Wellcome Trust Genes to Cognition Programme. We thank the Gene Expression and Genotyping Core Facility at the Case Comprehensive Cancer Center at CWRU and the Mouse Behavioral Phenotyping Laboratory Core Facility in the Neurodevelopmental Disorders Research Center at University of North Carolina, Chapel Hill. We also thank Dr. Blaine Armbruster for his technical help.
- Correspondence should be addressed to Dr. Bryan L. Roth, Department of Pharmacology, University of North Carolina, 4009 Genetics Medicine Building, CB#7365, Chapel Hill, NC 27599-7365. bryan_roth{at}med.unc.edu
Online Impact